Press release
Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments
– Following approval on June 22, the first patient received commercially reimbursed ELEVIDYS (delandistrogene moxeparvovec-rokl), earlier today – Total
About this update from Sarepta Therapeutics, Inc.
[{"type":"text","content":"\n– Following approval on June 22, the first patient received commercially reimbursed ELEVIDYS (delandistrogene moxeparvovec-rokl), earlier today\n\n\n– Total revenues, which consist of net product revenues and collaboration revenues, for the second quarter 2023 totaled $261.2 million\n\n\n– Net product revenues for the second quarter 2023 totaled $239.0 million, a 13% increase over the same quarter of prior year\n\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter 2023.\n\n\n“With a positive Advisory Committee vote followed by the approval of ELEVIDYS in June, this quarter marks an historic milestone in the treatment of Duchenne muscular dystrophy. The launch of ELEVIDYS is off to a great start, with our first reimbursed infusion today, ahead of plan. In addition to making this launch a success, our paramount goal is to translate a positive result in our confirmatory trial, EMBARK, later this year to a broad label as rapidly as possible,” said Doug Ingram, president and chief executive officer, Sarepta. “Even as we focus on the launch of our fourth approved therapy, we have remained committed to serving the community with our three approved PMO therapies. Achieving net product revenue in the second quarter of $239.0 million on combined sales of EXONDYS 51, AMONDYS 45, and VYONDYS 53, I am pleased to report that we continued to serve the Duchenne community.”\n\n\nSecond Quarter 2023 and Recent Developments:\n\n\n\nFirst ELEVIDYS commercial patient received treatment today: Following approval on June 22, the first patient received commercially reimbursed ELEVIDYS (delandistrogene moxeparvovec-rokl), earlier today.\n\n\n\nAnnounced FDA approval of ELEVIDYS, the first gene therapy to treat Duchenne muscular dystrophy: The company received FDA accelerated approval of ELEVIDYS (delandistrogene moxeparvovec-rokl), an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene. This indication is approved under accelerated approval based on expression of the protein produced by ELEVIDYS in skeletal muscle observed in patients treated with ELEVIDYS. ELEVIDY...